Effects of Lavandula angustifolia essential oil on Interleukin 23 and Brain-Derived neurotrophic factor gene expression in peripheral blood mononuclear cells of multiple sclerosis patients
Archives of Medical Laboratory Sciences,
Vol. 3 No. 2 (2017),
16 October 2017
https://doi.org/10.22037/amls.v3i2.19533
Abstract
Introduction: We aimed to determine the effect of lavandula angustifolia essential oil (LEO) on IL-23 and brain-derived neurotrophic factor (BDNF) gene expressions in peripheral blood mononuclear cells (PBMCs) of relapse-remitting MS (RRMS) patients.
Methods: LEO was prepared using the hydrodistilation method on the plants aerial parts. 8 female RRMS patients and 8 healthy sex and age matched controls were entered into this study. PBMC cells were separated using Ficoll method and were treated with a concentration of 225 µg/ml LEO which and then the mRNAs were used for determining the effects of LEO on IL-23 and BDNF gene expressions using Quantitative Real Time PCR technique. Moreover in order to determine the anti-inflammatory effects of LEO, we measured the gene expression of IL-6 and IL-23 in stimulated healthy PBMC cells treated with LEO.
Results: Results showed that there is no significant difference between PBMC of patients compared to healthy controls in case of IL-23 gene expression. Moreover, LEO has no significant effect on gene expression of IL-23 in PBMC of neither patients nor control. Also the results showed that BDNF gene expression is reduced to 41% compared to healthy controls and LEO can increase the BDNF gene expression by 81% in patients PBMCs. Moreover we observed that LEO can significantly reduce the LPS stimulated IL-6 gene expression in healthy PBMCs but had no significant effect on IL-23 gene expression.
Conclusion: The present study demonstrated that L.angustifolia essential oil may have a protective effect against neuron damage via increasing the gene expression of BDNF in PBMCs from RRMS patients. However, further studies are necessary to confirm our results.
- Lavandula Angustifolia
- PBMC
- RRMS
- IL-23
- BDNF
- Quantitative Real Time PCR
How to Cite
References
Marrie RA. Environmental risk factors in multiple sclerosis aetiology. The Lancet Neurology. 2004;3(12):709-18.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of neurology. 2011;69(2):292-302.
Compston A, Coles A. Multiple sclerosis. Lancet (London, England). 2008;372(9648):1502-17.
Maddur MS, Miossec P, Kaveri SV, Bayry J. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. The American journal of pathology. 2012;181(1):8-18.
Jadidi‐Niaragh F, Mirshafiey A. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scandinavian journal of immunology. 2011;74(1):1-13.
Yannam GR, Gutti T, Poluektova LY. IL-23 in infections, inflammation, autoimmunity and cancer: possible role in HIV-1 and AIDS. Journal of Neuroimmune Pharmacology. 2012;7(1):95-112.
Cua DJ, Sherlock J, Chen Y, Murphy CA. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003;421(6924):744.
Gyülvészi G, Haak S, Becher B. IL‐23‐driven encephalo‐tropism and Th17 polarization during CNS‐inflammation in vivo. European journal of immunology. 2009;39(7):1864-9.
Cala CM, Moseley CE, Steele C, Dowdy SM, Cutter GR, Ness JM, et al. T cell cytokine signatures: biomarkers in pediatric multiple sclerosis. Journal of neuroimmunology. 2016;297:1-8.
Comabella M, Montalban X. Body fluid biomarkers in multiple sclerosis. The Lancet Neurology. 2014;13(1):113-26.
Shajarian M, Alsahebfosoul F, Etemadifar M, Sedaghat N, Shahbazi M, Firouzabadi FP, et al. IL-23 plasma level measurement in relapsing remitting multiple sclerosis (RRMS) patients compared to healthy subjects. Immunological investigations. 2015;44(1):36-44.
Wen S-R, Liu G-J, Feng R-N, Gong F-C, Zhong H, Duan S-R, et al. Increased levels of IL-23 and osteopontin in serum and cerebrospinal fluid of multiple sclerosis patients. Journal of neuroimmunology. 2012;244(1):94-6.
Stadelmann C, Kerschensteiner M, Misgeld T, Brück W, Hohlfeld R, Lassmann H. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain. 2002;125(1):75-85.
Lee R, Kermani P, Teng KK, Hempstead BL. Regulation of cell survival by secreted proneurotrophins. Science. 2001;294(5548):1945-8.
Lu B, Nagappan G, Lu Y. BDNF and synaptic plasticity, cognitive function, and dysfunction. Neurotrophic Factors: Springer; 2014. p. 223-50.
Pang PT, Teng HK, Zaitsev E, Woo NT, Sakata K, Zhen S, et al. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science. 2004;306(5695):487-91.
Reichardt LF. Neurotrophin-regulated signalling pathways. Philosophical Transactions of the Royal Society of London B: Biological Sciences. 2006;361(1473):1545-64.
Lühder F, Gold R, Flügel A, Linker RA. Brain-derived neurotrophic factor in neuroimmunology: lessons learned from multiple sclerosis patients and experimental autoimmune encephalomyelitis models. Archivum immunologiae et therapiae experimentalis. 2013;61(2):95-105.
Zhou X-F, Rush RA. Endogenous brain-derived neurotrophic factor is anterogradely transported in primary sensory neurons. Neuroscience. 1996;74(4):945-51.
Cavanagh H, Wilkinson J. Biological activities of lavender essential oil. Phytotherapy research. 2002;16(4):301-8.
Denner SS. Lavandula angustifolia miller: english lavender. Holistic Nursing Practice. 2009;23(1):57-64.
Koulivand PH, Khaleghi Ghadiri M, Gorji A. Lavender and the nervous system. Evidence-Based Complementary and Alternative Medicine. 2013;2013.
Wang D, Yuan X, Liu T, Liu L, Hu Y, Wang Z, et al. Neuroprotective activity of lavender oil on transient focal cerebral ischemia in mice. Molecules. 2012;17(8):9803-17.
Pardo G, Jones DE. The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. Journal of neurology. 2017;264(12):2351-74.
Algieri F, Rodriguez-Nogales A, Vezza T, Garrido-Mesa J, Garrido-Mesa N, Utrilla MP, et al. Anti-inflammatory activity of hydroalcoholic extracts of Lavandula dentata L. and Lavandula stoechas L. Journal of ethnopharmacology. 2016;190:142-58.
Huang M-Y, Liao M-H, Wang Y-K, Huang Y-S, Wen H-C. Effect of lavender essential oil on LPS-stimulated inflammation. The American journal of Chinese medicine. 2012;40(04):845-59.
Ma J, Xu H, Wu J, Qu C, Sun F, Xu S. Linalool inhibits cigarette smoke-induced lung inflammation by inhibiting NF-κB activation. International immunopharmacology. 2015;29(2):708-13.
Mazloom H, Alizadeh S, Pasalar P, Esfahani EN, Meshkani R. Downregulated microRNA-155 expression in peripheral blood mononuclear cells of type 2 diabetic patients is not correlated with increased inflammatory cytokine production. Cytokine. 2015;76(2):403-8.
Codarri L, Gyülvészi G, Tosevski V, Hesske L, Fontana A, Magnenat L, et al. ROR [gamma] t drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nature immunology. 2011;12(6):560-7.
Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nature medicine. 2007;13(10):1173.
Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24(2):179-89.
Longbrake EE, Racke MK. Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? Expert review of neurotherapeutics. 2009;9(3):319-21.
Li Y, Chu N, Hu A, Gran B, Rostami A, Zhang G-X. Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia. Brain. 2006;130(2):490-501.
Hasheminia SJ, Tolouei S, Zarkesh-Esfahani SH, Shaygannejad V, Shirzad HA, Torabi R, et al. Cytokine gene expression in newly diagnosed multiple sclerosis patients. Iranian Journal of Allergy, Asthma and Immunology. 2015;14(2):208.
Azoulay D, Urshansky N, Karni A. Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced neuroprotection. Journal of neuroimmunology. 2008;195(1):186-93.
Urshansky N, Mausner-Fainberg K, Auriel E, Regev K, Farhum F, Karni A. Dysregulated neurotrophin mRNA production by immune cells of patients with relapsing remitting multiple sclerosis. Journal of the neurological sciences. 2010;295(1):31-7.
Sarchielli P, Greco L, Stipa A, Floridi A, Gallai V. Brain-derived neurotrophic factor in patients with multiple sclerosis. Journal of neuroimmunology. 2002;132(1):180-8.
Azoulay D, Vachapova V, Shihman B, Miler A, Karni A. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. Journal of neuroimmunology. 2005;167(1):215-8.
Mehrpour M, Akhoundi FH, Delgosha M, Keyvani H, Motamed MR, Sheibani B, et al. Increased serum brain-derived neurotrophic factor in multiple sclerosis patients on interferon-β and its impact on functional abilities. The neurologist. 2015;20(4):57-60.
Xu P, Wang K, Lu C, Dong L, Gao L, Yan M, et al. The Protective Effect of Lavender Essential Oil and Its Main Component Linalool against the Cognitive Deficits Induced by D-Galactose and Aluminum Trichloride in Mice. Evidence-Based Complementary and Alternative Medicine. 2017;2017.
- Abstract Viewed: 722 times
- PDF Downloaded: 329 times